E-mail: mario.boccadoro@unito.it
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients
- A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients
- Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial
- Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients
- Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients
- Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study
- DROPLET DIGITAL PCR (DDPCR) AND REAL-TIME PCR (RQ-PCR): A HEAD TO HEAD COMPARISON FOR MRD DETECTION IN MYELOMA (MM) MANTLE CELL LYMPHOMA (MCL) AND FOLLICULAR LYMPHOMA (FL)
- EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
- EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS
- EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL
- GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
- Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
- IMPACT OF CONTINUOUS TREATMENT VS FIXED DURATION OF THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS: PFS1, PFS2, OS ENDPOINTS
- Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
- Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM
- IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL
- LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS
- MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL
- REVISED-INTERNATIONAL STAGING SYSTEM (R-ISS): A NEW AND SIMPLE PROGNOSTIC ASSESSMENT FOR MULTIPLE MYELOMA.
- SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE: A META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD)
- Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
- The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy
